Stock Events

Stock Events

uniQure N.V. 

$20.91
107
-$2.08-9.05%Friday 06:38

Statistics

Day High
21.02
Day Low
20.53
52W High
50
52W Low
19.75
Volume
204
Avg. Volume
-
Mkt Cap
1.45B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 4Expected
Q3 2025
Q1 2026
Q2 2026
Q3 2026
-1.38
-1.19
-1.01
-0.82
Expected EPS
-0.915393
Actual EPS
-0.88

Financials

-1,236%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
16.1MRevenue
-198.97MNet Income

Analyst Ratings

$57.00Average Price Target
The highest estimate is ⁦80.00⁩.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QURE.BOATS. It's not an investment recommendation.
NVIDIA
22
NVDA
Tesla
19
TSLA
Alphabet
18
GOOGL
AMD
18
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical Inc. develops and commercializes innovative therapies for rare genetic diseases, overlapping with uniQure's target market.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc., through its acquisition of Bamboo Therapeutics and Spark Therapeutics, has expanded into gene therapy, making it a competitor in the same field as uniQure.
Regenxbio
RGNX
Mkt Cap475.29M
REGENXBIO Inc. is a biotechnology company that develops AAV-based gene therapies for genetic and other diseases, competing in the same space as uniQure.
Sarepta Therapeutics
SRPT
Mkt Cap1.97B
Sarepta Therapeutics, Inc. specializes in the discovery and development of RNA-based and gene therapy treatments for rare diseases, making it a competitor in the gene therapy market.
Intellia Therapeutics
NTLA
Mkt Cap1.75B
Intellia Therapeutics, Inc. is involved in CRISPR/Cas9 gene editing, a next-generation technology that could compete with uniQure's gene therapy approaches.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics AG focuses on the development of gene-based medicines using the CRISPR/Cas9 system, competing in the broader gene therapy and editing market alongside uniQure.

About

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Show More
CEO
ISIN
NL0010696654

Listings

MX
MX
QUREN.MX
STU
DE
UQ1.STU
XNAS
US
QURE
LSE
GB
0EE0.LSE

0 Comments

Share your thoughts

FAQs

What is uniQure N.V. stock price today?▼
The current price of QURE.BOATS is $20.91 USD — it has decreased by -9.05% in the past 24 hours. Watch uniQure N.V. stock price performance more closely on the chart.
What is uniQure N.V. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange uniQure N.V. stocks are traded under the ticker QURE.BOATS.
What is uniQure N.V. market cap?▼
Today uniQure N.V. has the market capitalization of 1.45B
When is the next uniQure N.V. earnings date?▼
uniQure N.V. is going to release the next earnings report on March 1, 2027.
What were uniQure N.V. earnings last quarter?▼
QURE.BOATS earnings for the last quarter are -0.88 USD per share, whereas the estimation was -0.92 USD resulting in a +3.87% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is uniQure N.V. revenue for the last year?▼
uniQure N.V. revenue for the last year amounts to 16.1M USD.
What is uniQure N.V. net income for the last year?▼
QURE.BOATS net income for the last year is -198.97M USD.
In which sector is uniQure N.V. located?▼
uniQure N.V. operates in the Other sector.
When did uniQure N.V. complete a stock split?▼
uniQure N.V. has not had any recent stock splits.